After three and a half years after the SARS-CoV-2 betacoronavirus began infecting people, 183 separate vaccines have entered clinical development.
Given this unprecedented response by vaccine developers, it could easily be assumed that COVID-19 vaccines have revealed all there is to know.
However, in The Lancet Respiratory Medicine, Gustavo Dayan and colleagues report the results of a phase 3 efficacy trial of a bivalent protein-based SARS-CoV-2 vaccine, offering new insights into vaccine-mediated protection against COVID-19.
Protein-based Vaccines Reduce COVID-19 Symptoms
BNT162b2 Vaccination Linked to Lower Risk for COVID-19 Encounters in Children Under 5
Vaccination linked to reduced odds ratio of COVID-19-related emergency department or urgent care encounter, outpatient visits
Tobacco, Cannabis Use Tied to High Rates of Self-Reported Mental Health Issues
Daily use of cigarettes, e-cigarettes, and cannabis associated with both anxiety and depression